BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int 2021;100:S1-S276. [PMID: 34556256 DOI: 10.1016/j.kint.2021.05.021] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 9.0] [Reference Citation Analysis]
Number Citing Articles
1 Oda Y, Sawa N, Nozu K, Ubara Y. Refractory focal segmental glomerulosclerosis caused by Alport syndrome detected by genetic testing after three decades. BMJ Case Rep 2022;15:e247393. [PMID: 35288428 DOI: 10.1136/bcr-2021-247393] [Reference Citation Analysis]
2 Neves PDMDM, Muniz MPR, Morgantetti GF, Cutrim ÉMM, Macieira CDA, Salgado-filho N, Lages JS, Brito DJDA, Cunha KDA, Gatto GC, Silva GEB. Membranous Nephropathy Secondary to Graves’ Disease: A Case Report. Front Immunol 2022;13:824124. [DOI: 10.3389/fimmu.2022.824124] [Reference Citation Analysis]
3 Fu J, Campbell KN. Urine Single-Cell RNA Sequencing in Focal Segmental Glomerulosclerosis—Hope for the Future. Kidney International Reports 2021. [DOI: 10.1016/j.ekir.2021.12.002] [Reference Citation Analysis]
4 Zhou X, Wang N, Zhang Y, Yu P. Expression of CCL2, FOS, and JUN May Help to Distinguish Patients With IgA Nephropathy From Healthy Controls. Front Physiol 2022;13:840890. [DOI: 10.3389/fphys.2022.840890] [Reference Citation Analysis]
5 He J, Cui D, Zhou X, Chen P, Li Y, Zhang X, Wang Y, Gan T, Liu L, Shi S, Zhu L, Hou P, Lv J, Zhang H. Concurrent IgA Nephropathy and Membranous Nephropathy, Is It an Overlap Syndrome? Front Immunol 2022;13:846323. [DOI: 10.3389/fimmu.2022.846323] [Reference Citation Analysis]
6 Tian Z, Li Y, Xie Y, Yang Y, Xu J. Efficacy and safety of tacrolimus combined with corticosteroids in patients with idiopathic membranous nephropathy: a systematic review and meta-analysis of randomized controlled trials. Int Urol Nephrol. [DOI: 10.1007/s11255-022-03169-6] [Reference Citation Analysis]
7 Podzolkov VI, Dragomiretskaya NA, Kazadaeva AV, Belyaev YG, Tolmacheva AV. Galectin-3 as a Marker of Cardiorenal Syndrome in Patients with Chronic Heart Failure. Racionalʹnaâ farmakoterapiâ v kardiologii 2022;18:153-9. [DOI: 10.20996/1819-6446-2022-04-04] [Reference Citation Analysis]
8 Nishi H. Aptamer-Based Proteomic Platform for Human Immune-Mediated Kidney Diseases. Kidney International Reports 2022. [DOI: 10.1016/j.ekir.2022.05.010] [Reference Citation Analysis]
9 Yamatani S, Kono K, Fujii H, Hirabayashi K, Shimizu M, Watanabe K, Goto S, Nishi S. Comparison of two protocols for steroid pulse therapy in patients with IgA nephropathy: a retrospective observational study. BMC Nephrol 2022;23:153. [PMID: 35436909 DOI: 10.1186/s12882-022-02791-x] [Reference Citation Analysis]
10 Cui Y, Zhai YL, Qi YY, Liu XR, Zhao YF, Lv F, Han LP, Zhao ZZ. The comprehensive analysis of clinical trials registration for IgA nephropathy therapy on ClinicalTrials.gov. Ren Fail 2022;44:461-72. [PMID: 35272573 DOI: 10.1080/0886022X.2022.2048017] [Reference Citation Analysis]
11 An N, Yang C, Wu HL, Guo Y, Huang XJ, Huang TS, Wu ZH, Xue J, Chen RH, Li ZH, Pan QJ, Liu HF. Hydroxychloroquine administration exacerbates acute kidney injury complicated by lupus nephritis. Arthritis Res Ther 2022;24:6. [PMID: 34980245 DOI: 10.1186/s13075-021-02700-x] [Reference Citation Analysis]
12 Campbell KN. Oral Glucocorticoids for IgA Nephropathy. JAMA 2022;327:1872-4. [PMID: 35579657 DOI: 10.1001/jama.2022.4638] [Reference Citation Analysis]
13 Yu G, Cheng J, Li H, Li X, Chen J. Comparison of 24-h Urine Protein, Urine Albumin-to-Creatinine Ratio, and Protein-to-Creatinine Ratio in IgA Nephropathy. Front Med 2022;9:809245. [DOI: 10.3389/fmed.2022.809245] [Reference Citation Analysis]
14 Rood IM, Bavinck A, Lipska-Ziętkiewicz BS, Lugtenberg D, Schaefer F, Deegens JKJ, Wetzels JFM. Later Response to Corticosteroids in Adults With Primary Focal Segmental Glomerular Sclerosis Is Associated With Favorable Outcomes. Kidney Int Rep 2022;7:87-98. [PMID: 35005317 DOI: 10.1016/j.ekir.2021.10.016] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Mathew G, Sinha A, Ahmed A, Grewal N, Khandelwal P, Hari P, Bagga A. Efficacy of rituximab versus tacrolimus in difficult-to-treat steroid-sensitive nephrotic syndrome: an open-label pilot randomized controlled trial. Pediatr Nephrol. [DOI: 10.1007/s00467-022-05475-8] [Reference Citation Analysis]
16 Susekov AV. Topical issues concerning modern lipid-lowering therapy. Consilium Medicum 2022;24:20-7. [DOI: 10.26442/20751753.2022.1.201484] [Reference Citation Analysis]
17 Yap DYH, Chan TM. What is the ideal duration of maintenance therapy for lupus nephritis? Expert Review of Clinical Immunology. [DOI: 10.1080/1744666x.2022.2056020] [Reference Citation Analysis]
18 Benoit SW, Khandelwal P, Grimley MS. A case of treatment‐resistant membranous nephropathy associated with graft versus host disease successfully treated with daratumumab. Pediatric Transplantation. [DOI: 10.1111/petr.14263] [Reference Citation Analysis]
19 Li Y, Xiong Y, Huang T, Liu X, Xu G. Clinical efficacy and safety of full-dose versus half-dose corticosteroids plus leflunomide for IgA nephropathy. BMC Nephrol 2021;22:364. [PMID: 34736419 DOI: 10.1186/s12882-021-02555-z] [Reference Citation Analysis]
20 Bernardi S, Innocenti S, Charbit M, Boyer O. Late Onset of ANCA Vasculitis as a Side Effect of Levamisole Treatment in Nephrotic Syndrome. Medicina 2022;58:650. [DOI: 10.3390/medicina58050650] [Reference Citation Analysis]
21 Lv J, Wong MG, Hladunewich MA, Jha V, Hooi LS, Monaghan H, Zhao M, Barbour S, Jardine MJ, Reich HN, Cattran D, Glassock R, Levin A, Wheeler DC, Woodward M, Billot L, Stepien S, Rogers K, Chan TM, Liu ZH, Johnson DW, Cass A, Feehally J, Floege J, Remuzzi G, Wu Y, Agarwal R, Zhang H, Perkovic V; TESTING Study Group. Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial. JAMA 2022;327:1888-98. [PMID: 35579642 DOI: 10.1001/jama.2022.5368] [Reference Citation Analysis]
22 Molnár A, Studinger P, Ledó N. Diagnostic and Therapeutic Approach in ANCA-Associated Glomerulonephritis: A Review on Management Strategies. Front Med 2022;9:884188. [DOI: 10.3389/fmed.2022.884188] [Reference Citation Analysis]
23 Molnár A, Thomas MJ, Fintha A, Kardos M, Dobi D, Tislér A, Ledó N. Kidney biopsy-based epidemiologic analysis shows growing biopsy rate among the elderly. Sci Rep 2021;11. [DOI: 10.1038/s41598-021-04274-9] [Reference Citation Analysis]
24 Ding Y, Li H, Xu L, Wang Y, Yang H. Identification and Validation of Prognostic Biomarkers Specifically Expressed in Macrophage in IgA Nephropathy Patients Based on Integrated Bioinformatics Analyses. Front Mol Biosci 2022;9:884588. [DOI: 10.3389/fmolb.2022.884588] [Reference Citation Analysis]
25 Kim ES, Keam SJ. Voclosporin in lupus nephritis: a profile of its use. Drugs Ther Perspect. [DOI: 10.1007/s40267-021-00887-2] [Reference Citation Analysis]
26 Asim M, Akhtar M. Epidemiology, Impact, and Management Strategies of Anti-Glomerular Basement Membrane Disease. IJNRD 2022;Volume 15:129-38. [DOI: 10.2147/ijnrd.s326427] [Reference Citation Analysis]
27 Zhu H, Xu L, Liu X, Liu B, Zhai C, Wang R, Yang X. Anti-PLA2R antibody measured by ELISA predicts the risk of vein thrombosis in patients with primary membranous nephropathy. Ren Fail 2022;44:594-600. [PMID: 35380081 DOI: 10.1080/0886022X.2022.2057861] [Reference Citation Analysis]
28 Mejia-Vilet JM, Malvar A, Arazi A, Rovin BH. The lupus nephritis management renaissance. Kidney Int 2021:S0085-2538(21)00874-7. [PMID: 34619230 DOI: 10.1016/j.kint.2021.09.012] [Reference Citation Analysis]
29 Troyanov S, Hladunewich MA, Reich HN. How Should Pathology Findings Influence Treatment in IgA Nephropathy? Kidney Int Rep 2022;7:3-5. [PMID: 35005306 DOI: 10.1016/j.ekir.2021.11.001] [Reference Citation Analysis]
30 Diefenhardt P, Osterholt T, Brinkkötter P. [Nephrotic syndrome: Current understanding and future therapies]. Dtsch Med Wochenschr 2022;147:332-6. [PMID: 35291039 DOI: 10.1055/a-1334-2135] [Reference Citation Analysis]
31 Liu Q, Liu J, Lin B, Zhang Y, Ma M, Yang M, Qin X. Novel Biomarkers in Membranous Nephropathy. Front Immunol 2022;13:845767. [DOI: 10.3389/fimmu.2022.845767] [Reference Citation Analysis]
32 Nikolopoulos D, Fotis L, Gioti O, Fanouriakis A. Tailored treatment strategies and future directions in systemic lupus erythematosus. Rheumatol Int 2022. [PMID: 35449237 DOI: 10.1007/s00296-022-05133-0] [Reference Citation Analysis]
33 Caza TN, Al-Rabadi LF, Beck LH Jr. How Times Have Changed! A Cornucopia of Antigens for Membranous Nephropathy. Front Immunol 2021;12:800242. [PMID: 34899763 DOI: 10.3389/fimmu.2021.800242] [Reference Citation Analysis]
34 Jäger C, Stampf S, Molyneux K, Barratt J, Golshayan D, Hadaya K, Huynh-Do U, Binet FI, Mueller TF, Koller M, Kim MJ. Recurrence of IgA nephropathy after kidney transplantation: experience from the Swiss transplant cohort study. BMC Nephrol 2022;23:178. [PMID: 35538438 DOI: 10.1186/s12882-022-02802-x] [Reference Citation Analysis]
35 Wang Q, Wang Q, Gao Y, Tang C, Gao Z, Hu Z. Case Report: Membranous Nephropathy Secondary to Cobalamin C Disease. Front Med 2022;8:807017. [DOI: 10.3389/fmed.2021.807017] [Reference Citation Analysis]
36 Cirillo L, Ravaglia F, Errichiello C, Anders H, Romagnani P, Becherucci F. Expectations in children with glomerular diseases from SGLT2 inhibitors. Pediatr Nephrol. [DOI: 10.1007/s00467-022-05504-6] [Reference Citation Analysis]